"The U.S. Food and Drug Administration today approved Clinolipid (lipid injectable emulsion, USP) for intravenous feeding (parenteral nutrition) in adult patients, providing a source of calories and essential fatty acids for adult patients who are"...
(Generic versions may still be available.)
Oxytetracycline is indicated in infections caused by the following microorganisms:
Mycoplasma pneumoniae (PPLO, Eaton Agent),
Agents of psittacosis and ornithosis,
The following gram-negative microorganisms:
Haemophilus ducreyi (chancroid),
Pasteurella pestis, and Pasteurella tularensis,
Brucella species (in conjunction with streptomycin).
Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended.
Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:
Enterobacter aerogenes (formerly Aerobacter aerogenes ),
Mima species and Herellea species,
Haemophilus influenzae (respiratory infections),
Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:
Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive.
Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections.
When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to:
Fusobacterium fusiforme (Vincent's infection),
Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence.
To reduce the development of drug-resistant bacteria and maintain effectiveness of Terramycin (oxytetracycline) IM and other antibacterial drugs, Terramycin (oxytetracycline) IM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
DOSAGE AND ADMINISTRATION
Adults: The usual daily dose is 250 mg administered once every 24 hours or 300 mg given in divided doses at 8 to 12 hour intervals.
For children above eight years of age: 15-25 mg/kg of body weight up to a maximum of 250 mg per single daily injection. Dosage may be divided and given at 8 to 12 hour intervals.
Intramuscular therapy should be reserved for situations in which oral therapy is not feasible.
The intramuscular administration of oxytetracycline produces lower blood levels than oral administration in the recommended dosages. Patients placed on intramuscular oxytetracycline should be changed to the oral dosage form as soon as possible. If rapid, high blood levels are needed, oxytetracycline should be administered intravenously.
Terramycin (oxytetracycline) Intramuscular Solution is available as follows:
250 mg/2ml in 2 ml pre-scored glass ampules, packages of 5 (NDC 0049-0770-09).
100 mg/2ml in 2 ml pre-scored glass ampules, packages of 5 (NDC 0049-0760-09).
50 mg/ml in 10 ml multiple dose vials, packages of 5 (NDC 0049-0750-77).
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Terramycin Information
Report Problems to the Food and Drug Administration
Find out what women really need.